FierceBiotechOriginal article
{"a":[{"_":"Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win","$":{"href":"/biotech/amgens-horizon-acquired-fusion-protein-eases-sjogrens-severity-ph-3-win","hreflang":"en"}}]}
Phase 3positivePositive
AI Analysis
Summary
Amgen's Horizon-acquired investigational fusion protein achieved a Phase 3 win for Sjögren's disease, demonstrating efficacy in reducing disease severity. This positive result marks a significant milestone for the Horizon pipeline under Amgen's ownership.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial met primary endpoint, easing Sjögren's disease severity
Importance:7/10
Sentiment:
0.75
Phase 3 dataSjögren's diseaseAutoimmuneFusion proteinAmgenHorizon Therapeutics
Read the original article
Published by FierceBiotech on September 22, 2026 10:24 AM